For people with early-stage lung cancer (stages IB, II, or IIIA), surgery is often the first step. But what if you could boost the body's own defenses against the cancer before the operation? This study tested exactly that. Doctors gave patients a drug called pembrolizumab—a type of immunotherapy that helps the immune system recognize and attack cancer cells—both before and after surgery. The idea was to see if this approach was practical and safe. The main thing they wanted to know was simple: after getting the drug first, could patients still go through with their planned surgery? The study enrolled 35 people to find out. The researchers also wanted to look closely at what the drug does to the immune system. They focused on special immune cells called tumor-infiltrating lymphocytes (TILs), which are like the body's soldiers that can move into a tumor. The theory was that pembrolizumab might 'unmask' these cells, helping them recognize and target the cancer. While pembrolizumab is already approved for advanced lung cancer, using it around surgery for earlier stages was new. This trial was a crucial step to see if this two-part strategy—treatment before and after an operation—is something doctors can realistically offer patients.
Phase 2 trial of neoadjuvant/adjuvant pembrolizumab in stage IB-IIIA NSCLC completes enrollment of 35 patientsCan immunotherapy before lung cancer surgery help the immune system fight the tumor?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Review completed phase 2 data on neoadjuvant/adjuvant pembrolizumab for stage IB-IIIA NSCLC.
This multi-institutional, phase 2 clinical trial has completed enrollment of 35 patients to study neoadjuvant and adjuvant pembrolizumab for stage IB, II, or IIIA non-small cell lung cancer (NSCLC). The study design involves administering two doses of pembrolizumab prior to surgery (neoadjuvant therapy) and four doses after surgery (adjuvant therapy). Pembrolizumab is an investigational immunotherapy in this setting, though it is approved for advanced lung cancer. The presumed mechanism of action is the removal of T lymphocyte inhibition by masking the PD-1 receptor. The study's hypothesis is that this masking results in the activation and proliferation of T lymphocytes with specificities against tumor-associated antigens (TILs). The researchers hypothesize that, based on the response rate to pembrolizumab in advanced lung cancer, at least 20% of lung cancers would have TIL cells with specificities against tumor-associated antigens after pembrolizumab therapy. The primary outcome is surgical feasibility rate, measured by the number of subjects who undergo surgery following neoadjuvant pembrolizumab. The study started in January 2017, reached primary completion on March 19, 2019, and results were posted on February 18, 2020. The study is led by Neal Ready, MD, PhD. The abstract does not report specific efficacy results, safety data, or limitations of the study.
What this means for you:
A study tested giving immunotherapy before and after lung cancer surgery to see if it was a feasible approach. More on Non-Small Cell Lung Cancer
Meta-analysis of neoadjuvant anti-PD-1/PD-L1 plus chemotherapy in resectable NSCLC reports resection and response rates
Combining checkpoint inhibitors with chemotherapy helps more lung cancer patients get surgery safely
This meta-analysis synthesized outcomes from 1,885 patients with potentially resectable non-small cell lung cancer who received neoadjuvant …
A review of 1,885 patients found that adding immune therapy to standard chemo before surgery helped many get clean operations. About one in …
Real-world meta-analysis supports pembrolizumab for advanced NSCLC with high PD-L1
Real-world data confirms pembrolizumab offers long-term survival for advanced lung cancer patients
A systematic review and meta-analysis of real-world studies evaluated first-line pembrolizumab monotherapy for advanced NSCLC with high PD-L…
New data from thousands of patients shows pembrolizumab provides reliable long-term survival for advanced lung cancer without major safety s…
Pembrolizumab improves overall survival versus chemotherapy in Chinese patients with advanced NSCLC and PD-L1 expression
Five-year follow-up shows pembrolizumab extends life for Chinese lung cancer patients with high PD-L1
This Phase 3 trial evaluated pembrolizumab monotherapy against chemotherapy in Chinese patients with previously untreated locally advanced o…
A five-year look at a Chinese lung cancer trial shows pembrolizumab improved survival compared to chemotherapy for patients with high PD-L1 …
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
New drugs beat old ones for advanced lung cancer survival
This systematic review and network meta-analysis evaluated overall survival and progression-free survival across 15 Phase III randomized cli…
New drug combinations show better survival chances for advanced lung cancer patients whether their tumors express PD-L1 or not
View Original Abstract ↓
Status: COMPLETED | Phase: PHASE2
Condition(s): Non-small Cell Lung Carcinoma
Intervention(s): Pembrolizumab (DRUG)
This multi-institutional, phase 2 clinical trial is studying two doses of pembrolizumab administered prior to surgery (neoadjuvant therapy) and 4 doses administered after surgery (adjuvant therapy) for stage IB, II or IIIA non-small cell lung cancer. Pembrolizumab is a type of immunotherapy that may enhance the ability of the immune system to fight off cancer. The study will investigate the effects of pembrolizumab on the immune system and how certain immune cells, called TILs (tumor infiltrating lymphocytes), respond to pembrolizumab. Previous studies suggest that pembrolizumab could alter the immune cells in a way that the the immune cells identify cancer cells. Pembrolizumab has been approved for the treatment of advanced lung cancer, but is investigational in this setting.
Detailed: The presumed mechanism of action for pembrolizumab is the removal of T lymphocyte inhibition by masking the PD-1 receptor. Our hypothesis is that the masking of the PD-1 receptor by pembrolizumab results in the activation and proliferation of T lymphocytes with specificities against tumor associated antigens (TILs). In untreated lung cancer tumors, we would expect few tumors to have TIL cells with specificities against tumor associated antigens. Based on the response rate to pembrolizumab in advanced lung cancer, we hypothesize that at least 20% of lung cancers would have TIL cells with specificities against tumor associated antigens after pembrolizumab therapy.
Studying neoadjuvant pembrolizumab therapy is an attractive strategy for studying the immunologic changes caused by PD-1 (progra
Primary Outcome(s): Surgical Feasibility Rate as Measured by the Number of Subjects Who Undergo Surgery Following Neoadjuvant Pembrozulimab
Enrollment: 35 (ACTUAL)
Lead Sponsor: Neal Ready MD PhD
Start: 2017-01 | Primary Completion: 2019-03-19
Results posted: 2020-02-18
Real-world meta-analysis supports pembrolizumab for advanced NSCLC with high PD-L1
Real-world data confirms pembrolizumab offers long-term survival for advanced lung cancer patients
Related in Pulmonology & Critical Care
FDA Approves Provocholine (methacholine chloride) for Bronchial Airway Hyperreactivity Diagnosis
FDA approves new test to help diagnose asthma in certain patients
The FDA approved Provocholine (methacholine chloride) for diagnosing bronchial airway hyperreactivity in adults and children aged 5 years an…
The FDA approved Provocholine, a drug used in a breathing test to diagnose airway hyperreactivity in people aged 5 and older who may have as…
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
Immunotherapy combo extends survival in small cell lung cancer
This phase 3 RCT evaluated tislelizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated extensive-stage small cel…
Adding tislelizumab to chemo helped people with extensive-stage small cell lung cancer live 2 months longer, a phase 3 trial shows.
Lower PEEP may increase ventilator-free days in ventilated patients without ARDS
Lower breathing pressure settings showed modest benefits for some critically ill patients without lung injury
This Bayesian re-analysis of an RCT in 980 invasively ventilated critically ill patients without ARDS found that lower PEEP (0-5 cm H2O) com…
A re-analysis of data found that using the lowest safe breathing pressure might help some patients breathe easier. However, the overall bene…
Machine learning models show moderate accuracy predicting neoadjuvant immunotherapy response in NSCLC
Machine learning models predict how well lung cancer patients respond to immunotherapy
This systematic review and meta-analysis of 44 models found that machine learning predicts neoadjuvant immunotherapy response in resectable …
A new analysis of 44 models shows computer programs can guess which lung cancer patients will benefit from immunotherapy, though the study h…
From Other Specialties
Rapid advancements in imaging and blood-based biomarkers are transforming the diagnosis and management of ADRD
New guidelines help doctors tell delirium from dementia
This clinical guideline provides a narrative review on the evolving diagnostic and treatment landscape for Alzheimer's disease and related d…
Delirium is acute and fluctuating; dementia is chronic. New guidelines help doctors tell them apart.
ACTH and vigabatrin achieved full seizure control in a patient with Ververi-Brady syndrome
ACTH and Vigabatrin Show Promise for Rare Epilepsy Syndrome
This case report describes a 5-month-old male infant with Ververi-Brady syndrome and infantile epileptic spasms syndrome. The patient achiev…
A new gene variant linked to Ververi-Brady syndrome showed positive results when treated with a combination of ACTH and vigabatrin.
Postoperative AKI occurs in half of type A aortic dissection surgeries, meta-analysis finds
Factors Linked to Kidney Injury After Aortic Dissection Surgery
This meta-analysis of 44 studies (11,983 patients) found that 50.72% of patients undergoing surgery for Stanford type A aortic dissection de…
Over half of patients undergoing surgery for a specific type of aortic dissection develop acute kidney injury, with several risk factors ide…
Social and emotional skills training shows non-significant reductions in loneliness among children and adolescents
Social and Emotional Training Shows Promise for Youth Loneliness
This meta-analysis of 18 studies evaluated interventions targeting loneliness, including social and emotional skills training, in youth aged…
New research looks at how social and emotional skills training can help reduce feelings of loneliness in children and teenagers.